ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2022

Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.

Yu Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.